{"url_path":"/sec/tnxp/8-k/2026-06-29/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ** **Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1430306/0001493152-26-030408-index.html","accession_number":"0001493152-26-030408","cik":"0001430306","ticker":"TNXP","issuer_name":"Tonix Pharmaceuticals Holding Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1430306/0001493152-26-030408-index.html","primary_entity_key":"0001430306","primary_entity_name":"Tonix Pharmaceuticals Holding Corp."},"word_count":154,"has_tables":true,"body_markdown":"**Item 7.01** **Regulation FD Disclosure.**\n\n \n\nOn\nJune 29, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced that the first participant was enrolled in HORIZON,\na potentially pivotal Phase 2 study evaluating the Company’s TNX-102 SL 5.6 mg product candidate as a first-line monotherapy in\nadults with major depressive disorder (the “HORIZON Study”). A copy of the press release that discusses this matter is attached\nhereto as Exhibit 99.01\n\n \n\nThe\ninformation in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed”\nfor purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject\nto the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities\nAct of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}